1Freeman EE, White RG, Bakker R, et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub- Saharan Africa[J]. Vaccine, 2009,27(6) :940-946.
2Paz-Bailey G, Ramaswamy M, Hawkes SJ, et al. Herpes simplex virus type 2 : epidemiology and management options in developing countries[J]. Postgrad Med J, 2008,84(992) :299-306.
3Meignier B, Martin B, Whit|ey RJ, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and 117020. Ⅱ. Studies in immunocompetent and immunosupp ressed owl monkeys ( aotus trivirgatus) [J]. Infect Dis, 1990, 162 (3) : 13 - 21.
4Gyotoku T, Ono F, Aurelian L. Development of HSV-specific CD4 + Th1 responses and CD8 + cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK[J]. Vaccine. ,2002,20(21-22) :2796-2807.
5Stanberry LR,Cunningham AL,Mindel A,et al. Prospects for control of hopes simplex virus disease through immunization[J]. Clin Znfect Dis, 2000,30:549-566.
6Hoshino Y, Pesnicak L, Dowdel! KC,et al, Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 d15-29 and d15-29-41L in mice and guinea pigs [J]. Vaccine ,2008,26 (32) :4034-4040.
8Fotouhi F, Soleimanjahi H, Roostaee MH,et al. Enhancement of protective humoral immune responses against Herpes simplex virus- 2 in DNA-immunized guinea-pigs using protein boosting [ J ]. FEMS Immunol Med Microbiol, 2008,54( 1 ) : 18-26.
9Hans JW, Kazemier B. Selection of Recombinant, Library-Derived Antibody Fragments against p24 for Human Immunodeficieney Virus Type 1 Diagnostics[J]. Clinical and Diagnostic Laboratory Immunology, 1998,5:636-644.
10Cohen GH, Dietzschold B, Ponce de Leon M, et al. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoproteinD that stimulates the production of neutralizing antibody [ J ]. JVirol, 1984,49 ( 1 ) : 102-108.
4[1]Morimoto RI. Heat shock: the role of transient inducible responses in cell damage, transformation, and differentiation [J]. Cancer Cells, 1991,3(8):295-301.
6[3]Cheung RK, Dosch H. The growth transformation of human B cells involves superinduction of hsp70 and hsp90[J]. Virology, 1993,193(8):700-708.
7[5]Ohgitani E, Kobayashi K, Takeshita K et al. Biphasic transloacation of a 70 KDa heat shock protein in human cytomegalovirus-infected cells[J]. J Gen Virol, 1999,80(3):63-68.
8[7]Kabakov AE, Budagova KR, Bryantsev AL et al. Heat shock protein 70 or heat shock protein 27 overexpressed in human endothelial cells during posthypoxic reoxygenation can protect from delayed apoptosis[J]. Cell Stress Chaperones, 2003,8(4):335-347.
9[8]Latchman DS. Heat shock proteins and cardiac protection[J]. Cardiovasc Res, 2001,51(4):637-646.
10[9]Kumaraguru U, Gouffon CA Jr, Ivey RA et al. Antigenic peptides complexed to phylogenically diverse Hsp70s induce differential immune responses[J]. Cell Stress Chaperones,2003, 8(2):134-143.
1Liljeqvist JA, Svennerholm B, Bergstrom T. Conservation of type- specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates [J]. Clin Microbiol, 2000, 38 (12): 4517- 4522.
2Liljeqvist JA, Trybala E, Svennerholm B, et al. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies [J]. Gen Virol, 1998, 79 (5): 1215-1224.
3Grabowska AC, Jameson P, Laing S, et al. Identification of type specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, hut not by those infected with HSV-1 [J]. Gen Virol, 1999, 80: 1789-1798.
4Parker JN, Pfister LA, QueneUe D, et al. Genetically engineered herpes smiplex viruses that express IL-12 or GM-CSF as vaccine candidates[J]. Vaccine, 2006, 24 (10): 1644-1652.
5陆健.蛋向质纯化技术及应用[M].北京:化学工业出版社,2005.12-15.
6Liljeqvist JA,Svennerholm B,Bergstrom T. Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates [J]. Clin Microbiol, 2000, 38 (12): 4517‘ 4522.
7Liljeqvist JA, Trybala E, Svennerholm B, et al. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies [J]. Gen Virol, 1998, 79 (5): 1215-1224.
8Grabowska AC, Jameson P, Laing S, et al. Identification of type specific domains within glycoprotein G of herpes simplex virus type 2 ( HSV -2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-I [J]. Gen Virol, 1999, 80: 1789-1798.
9Parker JN,Pfister LA,Quenelle D,et al. Genetically engineered herpes smiplex viruses that express IL-12 or GM -CSF as vaccine candidates [J]. Vaccine, 2006 , 24 (10): 1644-1652.
